Trial Search Results

An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC)

The main purpose of this study is to collect information about the treatments that patients with Advanced Basal Cell Carcinoma (aBCC) and Basal Cell Carcinoma Nevus Syndrome (BCCNS) receive, including how well they work and how safe they are.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Genentech, Inc.

Stanford Investigator(s):

Eligibility


Inclusion Criteria:

   - Adult patients, >/= 18 years of age

   - Patients with basal cell carcinoma (BCC) who meet either of the following definitions:

      - Patients who were determined with advanced disease (aBCC) within 90 days prior to
      study enrollment, have not been diagnosed with basal cell carcinoma nevus
      syndrome (BCCNS) and have not been treated with an investigational or approved
      hedgehog pathway inhibitor

      - Patients with aBCC who have not been diagnosed with BCCNS and who were previously
      treated with vismodegib as part of Genentech study SHH4476g, SHH4437g, or
      SHH4811g (EAP)

      - Patients with BCCNS who either have aBCC or multiple BCCs of any stage as defined
      by protocol (may include patients previously enrolled in Genentech study
      SHH4476g, SHH4437g, or SHH4811g (EAP))

Exclusion Criteria:

   - Participation in a clinical trial within 90 days prior to study enrollment that has
   either involved treatment of aBCC or involved treatment with an investigational or
   approved hedgehog pathway inhibitor, except for patients treated with vismodegib as
   part of Genentech study SHH4476g, SHH4437g, or SHH4811g (EAP)

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting